 |
|
Still not a subscriber to JACC Imaging or JACC Interventions?
|
|
Correction
for
Opie and Schall, J Am Coll Cardiol 39 (2) 315-322.
Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy.
J Am Coll Cardiol 2002;39:315–22.
The authors have noted an error in Table 2 and Figure 1. The major implication is that reduction of nonfatal stroke associated with CCB use for hypertension does not outweigh but almost exactly balances the increase in MI. Corrected data show a relative risk for nonfatal stroke of 0.842 (p = 0.013). The relative risk for nonfatal MI remains 1.17 (p = 0.036). Respective Bonferroni-corrected p values for nonfatal stroke and nonfatal MI are 0.052 and 0.144. In addition, in type 2 diabetics, CCBs increased major cardiovascular events with relative risk not of 1.258 but of 1.339 (confidence intervals 1.074 to 1.670, p = 0.010), thereby more strongly supporting the provisional hypothesis that CCBs may be less safe than ACE inhibitors in diabetics. The revised Table 2 and Figure 1 are printed here. The authors apologize for the error.
View larger version (25K):
[in this window]
[in a new window]
|
Figure 1 Comparison between therapy based on calcium channel blockers (CCBs) and on conventional therapy. Note the decrease (p = 0.013) in nonfatal stroke and the increase in nonfatal myocardial infarction (MI) (p = 0.036). CV = cardiovascular.
|
|
|
|
